Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes

American Journal of Medicine

Volumn 116, Issue 2, 2004, Pages 119-129

  Rebeiz, Abdallah G ^a,b   Roe, Matthew T ^a   Alexander, John H ^a   Mahaffey, Kenneth W ^a   Granger, Christopher B ^a   Peterson, Eric D ^a   Califf, Robert M ^a   Harrington, Robert A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR;

ANGINA PECTORIS; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0347357655     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.09.028     Document Type: Review

References (97)

1. Braunwald E., Antman E., Beasley J., et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 36:2000;970-972.
2. Chesebro J., Fuster V. Thrombosis in unstable angina. N Engl J Med. 327:1992;192-194.
3. Fuster V., Badimon L., Badimon J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
4. Theroux P., Outmet H., McCans J., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111.
5. Invasive compared with noninvasive treatment in unstable coronary artery disease FRISC II prospective randomised multicentre study . Lancet. 354:1999;708-715.
6. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 344:2001;1879-1887.
7. Fox K., Poole-Wilson P., Henderson R., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction the British Heart Foundation RITA 3 randomised trial . Lancet. 360:2002;743-751.
8. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 336:1990;827-830.
9. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services. Clinical Practice Guideline Number 10: Unstable Angina: Diagnosis and Management. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services; 1994. AHCPR Publication 94-0602.
10. Cohen M., Adams P., Hawkins L., et al. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol. 66:1990;1287-1292.
11. Cohen M., Adams P., Parry G., et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users primary end points analysis from the ATACS trial: Antithrombotic Therapy in Acute Coronary Syndromes Research Group . Circulation. 89:1994;81-88.
12. Holdright D., Patel D., Cunningham D., et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 24:1994;39-45.
13. Gurfinkel E., Manos E., Mejail R., et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 26:1995;313-318.
14. Oler A., Whooley M., Oler J., et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina a meta-analysis . JAMA. 276:1996;811-815.
15. Granger C., Hirsh J., Califf R., et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction results from the GUSTO-I trial . Circulation. 93:1996;870-878.
16. Newby L., Harrington R., Bhapkar M., et al. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes insights from PARAGON A . J Thromb Thrombolysis. 14:2002;33-42.
17. Hirsh J., Levine M. Low molecular weight heparin. Blood. 79:1992;1-17.
18. Melandri G., Semprini F., Cervi V., et al. Comparison of efficacy of low molecular weight heparin (Parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol. 72:1993;450-454.
19. Granger C., Miller J., Bovill E., et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 91:1995;1929-1935.
20. Theroux P., Waters D., Lam J., et al. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med. 327:1992;141-145.
21. Samama M., Bara L., Gerotziafas G. Mechanisms for the antithrombotic activity in man of low-molecular-weight heparins (LMWHs). Haemostasis. 24:1994;105-117.
22. Warkentin T., Levine M., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
23. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction results of the TIMI 11B trial . Circulation. 100:1999;1593-1601.
24. Cohen M., Demers C., Gurfinkel E., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 337:1997;447-452.
25. Antman E., Cohen M., Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction TIMI 11B-ESSENCE meta-analysis . Circulation. 100:1999;1602-1608.
26. Antman E., Cohen M., McCabe C., et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J. 23:2002;308-314.
27. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Circulation. 106:2002;1893-1900.
28. Granger C. Strategies of patient care in acute coronary syndromes rationale for the Global Registry of Acute Coronary Events (GRACE) registry . Am J Cardiol. 86:2000;4-9.
29. Rabah M., Premmeneur J., Graham M., et al. Usefulness of intra-venous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol. 84:1999;1391-1395.
30. Bhatt D., Lee B., Casterella P., et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 41:2003;20-25.
31. Collet J., Montalescot G., Lison L., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 103:2001;658-663.
32. Kereiakes D.J., Montalescot G., Antman E., et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention an expert consensus . Am Heart J. 144:2002;615-624.
33. The SYNERGY trial study design and rationale . Am Heart J. 143:2002;952-960.
34. Low-molecular-weight heparin during instability in coronary artery disease, FRagmin during InStability in Coronary artery disease (FRISC) study group. Lancet. 347:1996;561-568.
35. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction FRAX.I.S . Eur Heart J. 20:1999;1553-1562.
36. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable CAD. Circulation. 96:1997;61-68.
37. Wong G., Giugliano R., Antman E. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA. 289:2003;331-342.
38. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
39. Serruys P., Herrman J., Simon R., et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 333:1995;757-763.
40. Bittl J., Strony J., Brinker J., et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Engl J Med. 333:1995;764-769.
41. Roe M., Granger C., Puma J., et al. Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Am J Cardiol. 88:2001;1403-1406.
42. Direct thrombin inhibitors in acute coronary syndromes principal results of a meta-analysis based on individual patients' data . Lancet. 359:2002;294-302.
43. Antman E.M., McCabe C.H., Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction observations from the TIMI 8 trial . Am Heart J. 143:2002;229-234.
44. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA. 289:2003;853-863.
45. Petitou M., Lormeau J., Choay J. Chemical synthesis of glycosaminoglycans new approaches to antithrombotic drugs . Nature. 350:1991;30-33.
46. Olson S., Bjork I., Sheffer R., et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions resolution of the antithrombin conformational change contribution to heparin rate enhancement . J Biol Chem. 267:1992;12528-12538.
47. Kaiser B., Jeske W., Walenga J., Fareed J. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagul Fibrinol. 10:1999;495-501.
48. Herbert J., Petitou M., Lormeau J., et al. SR 90107A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev. 15:1997;1-26.
49. Turpie A., Bauer K., Eriksson B., et al. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch Intern Med. 162:2002;1833-1840.
50. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity a phase II evaluation . Circulation. 102:2000;2726-2731.
51. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J. 22:2001;1716-1724.
52. Dyke C., Becker R., Kleiman N., et al. First experience with direct factor Xa inhibition in patients with stable coronary disease a pharmacokinetic and pharmacodynamic evaluation . Circulation. 105:2002;2385-2391.
53. Willerson J., Golino P., Eidt J., et al. Specific platelet mediators and unstable coronary artery lesions experimental evidence and potential clinical implications . Circulation. 80:1989;198-205.
54. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 330:1994;1287-1294.
55. Collaborative overview of randomised trials of antiplatelet therapy. I prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients . BMJ. 308:1994;81-106.
56. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 324:2002;71-86.
57. Gum P., Kottke-Marchant K., Welsh P., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 41:2003;961-965.
58. Gum P., Kottke-Marchant K., Poggio E., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 88:2001;230-235.
59. Pappas J., Westengard J., Bull B. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med. 118:1994;801-804.
60. Gurbel P.A., Bliden K.P., Hiatt B.L., et al. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity . Circulation. 107:2003;2908-2913.
61. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N Engl J Med. 338:1998;1488-1497.
62. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443.
63. Randomised placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb-IIIa blockade. Lancet. 352:1998;87-92.
64. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) a randomised, placebo-controlled trial . Lancet. 356:2000;2037-2044.
65. Karvouni E., Katritsis D., Ioannidis J. Intravenous glycoprotein IIb/ IIIa receptor antagonists reduce mortality after percutaneous coronary intervention. J Am Coll Cardiol. 41:2003;26-32.
66. Boersma E., Akkerhuis M., Theroux P., et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes. Early benefit during medical treatment only, with additional protection during coronary intervention. Circulation. 100:1999;2045-2048.
67. Simoons M.L., Armstrong P., Califf R., et al. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation the GUSTO IV-ACS randomised trial . Lancet. 357:2001;1915-1924.
68. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes a meta-analysis of all major randomised clinical trials . Lancet. 359:2002;189-198.
69. Marso S., Bhatt D., Roe M., et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation. 102:2000;2952-2958.
70. Peterson E., Pollack C.V. Jr, Roe M., et al. Early use of glycoprotein IIb-IIIa inhibitors in non-ST-elevation acute myocardial infarction observations from the National Registry of Myocardial Infarction 4 . J Am Coll Cardiol. 42:2003;45-53.
71. Moshfegh K., Redondo M., Julmy F., et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction enhanced inhibitory effects of combination therapy . J Am Coll Cardiol. 36:2000;699-705.
72. Bossavy J., Thalamas C., Sagnard L., et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood. 92:1998;1518-1525.
73. Mehta S., Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease . Eur Heart J. 21:2000;2033-2041.
74. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502.
75. Mehta S., Yusuf S., Peters R., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention the PCI-CURE study . Lancet. 358:2001;527-533.
76. Steinhubl S., Berger P., Mann J., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA. 288:2002;2411-2420.
77. Seyfarth H.J., Koksch M., Roethig G., et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J. 143:2002;118-123.
78. Muller I., Seyfarth M., Rudiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 85:2001;92-93.
79. Lincoff A., Harrington R., Califf R., et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition receptor suppression using integrilin therapy (PURSUIT) trial . Circulation. 102:2000;1093-1100.
80. Yusuf S., Mehta S., Zhao F., et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 107:2003;966-972.
81. Boden W., O'Rourke R., Crawford M., et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 338:1998;1785-1792.
82. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial. Circulation. 89:1994;1545-1556.
83. Lagerqvist B., Husted S., Kontny F., et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 40:2002;1902-1914.
84. Wallentin L., Lagerqvist B., Husted S., et al. Outcome at 1 year after an invasive compared with a noninvasive strategy in unstable coronary-artery disease the FRISC II invasive randomised trial . Lancet. 356:2000;9-16.
85. Morrow D., Antman E., Tanasijevic M., et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina a TIMI 11 B substudy . J Am Coll Cardiol. 36:2000;1812-1817.
86. Diderholm E., Andren B., Frostfeldt G., et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease the FRISC II invasive troponin T electrocardiogram substudy . Am Heart J. 143:2002;760-767.
87. Sabatine M., McCabe C., Morrow D., et al. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 143:2002;966-970.
88. Boersma E., Pieper K., Steyerberg E., et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 101:2000;2557-2567.
89. Lindahl B., Venge P., Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol. 29:1997;43-48.
90. Heeschen C., Hamm C., Goldmann B., et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 354:1999;1757-1762.
91. Newby L., Ohman E., Christenson R., et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status the PARAGON-B troponin T substudy . Circulation. 103:2001;2891-2896.
92. Morrow D., Cannon C., Rifai N., et al. Ability of minor elevations of troponin I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction results from a randomized trial . JAMA. 286:2001;2405-2412.
93. Toss H., Lindahl B., Siegbahn A., et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 96:1997;4204-4210.
94. Lenderink T., Boersma E., Heeschen C., et al. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J. 24:2003;77-85.
95. Heeschen C., Dimmeler S., Hamm C., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 348:2003;1104-1111.
96. Zebrack J., Anderson J., Maycock C., et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 82:2002;145-149.
97. Lindmark E., Diderholm E., Wallentin L., Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease effects of an early invasive or noninvasive strategy . JAMA. 286:2001;2107-2113.